Literature DB >> 8523531

Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

K Kurokohchi1, T Akatsuka, C D Pendleton, A Takamizawa, M Nishioka, M Battegay, S M Feinstone, J A Berzofsky.   

Abstract

To define cytotoxic T-cell (CTL) epitopes, the common approach involving the use of a series of overlapping synthetic peptides covering the whole protein sequence is impractical for large proteins. Motifs identify only a fraction of epitopes. To identify human CTL epitopes in the NS3 region of hepatitis C virus (HCV), we modified an approach using recombinant protein and the ability of short peptides to bind to class I major histocompatibility complex (MHC) molecules. Peripheral blood mononuclear cells from an HCV-infected patient were stimulated with a proteolytic digest of the recombinant NS3 protein to expand CTL to any active peptides in the digest. The digest was fractionated by reverse-phase high-performance liquid chromatography, and fractions were assessed for the ability to sensitize targets for lysis by CTL. The most active fraction was sequenced, identifying a 15-residue peptide (NS3-1J; TITTGAPVTYSTYGK). This sequence was confirmed to be the source of the activity by synthesis of the corresponding peptide. CTL lines specific for NS3-1J were established from two HCV-infected patients (both HLA-A2 and -B7 positive) by stimulation with the synthetic peptide in vitro. The CTL were HLA-A2 restricted, and the minimal epitope was mapped to a decapeptide NS3-1J (10.4). As this minimal epitope lacks the common HLA-A2-binding motif, this technique is useful for mapping CTL epitopes independent of known motifs and without the requirement for enormous numbers of overlapping peptides. Because this peptide is presented by the most common HLA class I molecule, present in almost half the population, it might be a useful component of a vaccine against HCV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8523531      PMCID: PMC189809     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.

Authors:  D F Hunt; R A Henderson; J Shabanowitz; K Sakaguchi; H Michel; N Sevilir; A L Cox; E Appella; V H Engelhard
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

2.  HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation.

Authors:  R A Henderson; H Michel; K Sakaguchi; J Shabanowitz; E Appella; D F Hunt; V H Engelhard
Journal:  Science       Date:  1992-03-06       Impact factor: 47.728

Review 3.  Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease.

Authors:  M Houghton; A Weiner; J Han; G Kuo; Q L Choo
Journal:  Hepatology       Date:  1991-08       Impact factor: 17.425

4.  Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules.

Authors:  M H Newberg; J P Ridge; D R Vining; R D Salter; V H Engelhard
Journal:  J Immunol       Date:  1992-07-01       Impact factor: 5.422

5.  Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells.

Authors:  S Hou; P C Doherty; M Zijlstra; R Jaenisch; J M Katz
Journal:  J Immunol       Date:  1992-08-15       Impact factor: 5.422

6.  Genomic structure of the human prototype strain H of hepatitis C virus: comparison with American and Japanese isolates.

Authors:  G Inchauspe; S Zebedee; D H Lee; M Sugitani; M Nasoff; A M Prince
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

7.  Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.

Authors:  A J Weiner; H M Geysen; C Christopherson; J E Hall; T J Mason; G Saracco; F Bonino; K Crawford; C D Marion; K A Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

8.  Precise prediction of a dominant class I MHC-restricted epitope of Listeria monocytogenes.

Authors:  E G Pamer; J T Harty; M J Bevan
Journal:  Nature       Date:  1991-10-31       Impact factor: 49.962

9.  Extracellular processing of peptide antigens that bind class I major histocompatibility molecules.

Authors:  L A Sherman; T A Burke; J A Biggs
Journal:  J Exp Med       Date:  1992-05-01       Impact factor: 14.307

10.  Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus 1 gp160 peptide for presentation by major histocompatibility complex class I molecules.

Authors:  S Kozlowski; M Corr; T Takeshita; L F Boyd; C D Pendleton; R N Germain; J A Berzofsky; D H Margulies
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

View more
  12 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

Authors:  D K Wong; D D Dudley; P B Dohrenwend; G M Lauer; R T Chung; D L Thomas; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 3.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.

Authors:  P Sarobe; C D Pendleton; T Akatsuka; D Lau; V H Engelhard; S M Feinstone; J A Berzofsky
Journal:  J Clin Invest       Date:  1998-09-15       Impact factor: 14.808

5.  The utility and limitations of current Web-available algorithms to predict peptides recognized by CD4 T cells in response to pathogen infection.

Authors:  Francisco A Chaves; Alvin H Lee; Jennifer L Nayak; Katherine A Richards; Andrea J Sant
Journal:  J Immunol       Date:  2012-03-30       Impact factor: 5.422

6.  Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.

Authors:  M E Major; K Mihalik; J Fernandez; J Seidman; D Kleiner; A A Kolykhalov; C M Rice; S M Feinstone
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Molecular and immunological significance of chimpanzee major histocompatibility complex haplotypes for hepatitis C virus immune response and vaccination studies.

Authors:  Eishiro Mizukoshi; Michelina Nascimbeni; Joshua B Blaustein; Kathleen Mihalik; Charles M Rice; T Jake Liang; Stephen M Feinstone; Barbara Rehermann
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

9.  CD28-negative CD8-positive cytotoxic T lymphocytes mediate hepatocellular damage in hepatitis C virus infection.

Authors:  Kazutaka Kurokohchi; Tsutomu Masaki; Keiji Arima; Yoshiaki Miyauchi; Toshiharu Funaki; Hirohito Yoneyama; Shuhei Yoshida; Akihiro Deguchi; Seiji Nakai; Seishiro Watanabe; Shigeki Kuriyama
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

Review 10.  Infectious diseases and immunity: special reference to major histocompatibility complex.

Authors:  N Singh; S Agrawal; A K Rastogi
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.